Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
July 10, 2019 08:30 ET
|
Myovant Sciences, Inc.
Digital insights study to include over 20,000 people and evaluate women’s menstrual experiences, including symptoms such as heavy menstrual bleeding and menstrual painPERIOD. Inc., a Myovant partner...
Myovant Sciences to Present at Upcoming June Investor Conferences
June 04, 2019 08:30 ET
|
Myovant Sciences, Inc.
BRISBANE, California and BASEL, Switzerland, June 04, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative...
Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
May 30, 2019 21:01 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif. and BASEL, Switzerland, May 30, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing...
Myovant Sciences Announces $100 Million Public Offering of Common Shares
May 29, 2019 16:16 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif. and BASEL, Switzerland, May 29, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing...
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
May 24, 2019 16:05 ET
|
Myovant Sciences, Inc.
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies expected over...
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 14, 2019 07:30 ET
|
Myovant Sciences, Inc.
- Phase 3 study met primary efficacy endpoint with highly statistically significant 73.4% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss-...
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 13, 2019 16:16 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, May 13, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s...